肿瘤细胞治疗研究
英文原题：Implantable CAR T cell factories enhance solid tumor treatment.
嵌合抗原受体（CAR）T 细胞疗法在白血病和淋巴瘤等血液肿瘤中取得了革命性成功。
嵌合抗原受体（CAR）T细胞疗法治疗白血病和淋巴瘤等血液系统恶性肿瘤已取得革命性成功。然而，其向实体瘤转化仍面临挑战，包括制造流程复杂、体内持久性短和治疗作用短暂。我们介绍一种名为“Drydux”的创新大孔生物材料支架，可快速、高效地在体内生成肿瘤特异性CAR-T细胞。Drydux从采集患者血液到制备CAR-T细胞仅需3天，为传统方法提供一种简化且成本效益高的替代方案。值得注意的是，Drydux生成的CAR-T细胞可在体内持续释放并保持功能和增强的持久性，超过150天，且细胞向记忆表型转变。传统CAR-T细胞疗法仅能暂时控制肿瘤，而等量Drydux细胞在多种动物肿瘤模型中诱导持久肿瘤缓解，包括系统性淋巴瘤、腹膜卵巢癌、转移性肺癌和原位胰腺癌。Drydux方法有望通过提供持久、快速且成本效益高的治疗，革新实体瘤CAR-T细胞疗法，并扩大患者获得这项突破性疗法的机会。
Chimeric Antigen Receptor (CAR) T cell therapy has produced revolutionary success in hematological cancers such as leukemia and lymphoma. Nonetheless, its translation to solid tumors faces challenges due to manufacturing complexities, short-lived in vivo persistence, and transient therapeutic impact. We introduce 'Drydux' - an innovative macroporous biomaterial scaffold designed for rapid, efficient in-situ generation of tumor-specific CAR T cells. Drydux expedites CAR T cell preparation with a mere three-day turnaround from patient blood collection, presenting a cost-effective, streamlined alternative to conventional methodologies. Notably, Drydux-enabled CAR T cells provide prolonged in vivo release, functionality, and enhanced persistence exceeding 150 days, with cells transitioning to memory phenotypes. Unlike conventional CAR T cell therapy, which offered only temporary tumor control, equivalent Drydux cell doses induced lasting tumor remission in various animal tumor models, including systemic lymphoma, peritoneal ovarian cancer, metastatic lung cancer, and orthotopic pancreatic cancer. Drydux's approach holds promise in revolutionizing solid tumor CAR T cell therapy by delivering durable, rapid, and cost-effective treatments and broadening patient accessibility to this groundbreaking therapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。
